Bladder cancer remains one of the most common and lethal diseases that cause approximately 150,000 deaths per year worldwide. Over the past two decades, the options currently available to patients with invasive disease remained essentially unchanged and no effective drugs have been approved in that time.
Cisplatin-based combination chemotherapy remains the standard of care for first-line systemic treatment of metastatic urothelial carcinoma. However, the major advances in understanding the genetic background of urothelial tumors open up a new therapeutic area. Here, we summarize the current state of development of targeted agents in urothelial cancer; with an emphasis on immune checkpoints inhibitors and FGFR targeted therapies that represent the most promising therapeutic approaches for invasive bladder cancer.
Critical reviews in oncology/hematology. 2015 Nov 09 [Epub ahead of print]
Mathieu Rouanne, Yohann Loriot, Thierry Lebret, Jean-Charles Soria
Department of Urology, Foch Hospital, Versailles-Saint-Quentin-en-Yvelines University, Suresnes, France; INSERM U981, Gustave Roussy Cancer Campus, Paris-South University, Villejuif, France. , INSERM U981, Gustave Roussy Cancer Campus, Paris-South University, Villejuif, France; Department of Cancer Medicine, Gustave Roussy Cancer Campus, Paris-South University, Villejuif, France. Department of Urology, Foch Hospital, Versailles-Saint-Quentin-en-Yvelines University, Suresnes, France. , INSERM U981, Gustave Roussy Cancer Campus, Paris-South University, Villejuif, France; Drug Development Department, Gustave Roussy Cancer Campus, Paris-South University, Villejuif, France.